Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT.

Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. eCollection 2017 Sep 12.

2.

Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Hemodialysis Patients.

Green MS, Tellor KB, Buckallew AR.

Hosp Pharm. 2017 Oct;52(9):623-627. doi: 10.1177/0018578717724799. Epub 2017 Aug 11.

PMID:
29276299
3.

Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.

Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C; ATTRACT Trial Investigators.

N Engl J Med. 2017 Dec 7;377(23):2240-2252. doi: 10.1056/NEJMoa1615066.

PMID:
29211671
4.

Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial.

Åsberg S, Hijazi Z, Norrving B, Terént A, Öhagen P, Oldgren J.

Trials. 2017 Dec 2;18(1):581. doi: 10.1186/s13063-017-2313-9.

5.

Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Yanik MV, Irvin MR, Beasley TM, Jacobson PA, Julian BA, Limdi NA.

Pharmacotherapy. 2017 Nov;37(11):1366-1373. doi: 10.1002/phar.2032. Epub 2017 Nov 2.

PMID:
28949423
6.

Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis.

Khan F, Rahman A, Carrier M, Kearon C, Schulman S, Couturaud F, Prandoni P, Eichinger S, Becattini C, Agnelli G, Büller HR, Brighton TA, Palareti G, Pinede L, Sabri E, Hutton B, Wells GA, Rodger MA; MARVELOUS Collaborators.

BMJ Open. 2017 Sep 21;7(9):16950. doi: 10.1136/bmjopen-2017-016950.

7.

Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation.

Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Lip GYH, Marín F.

Sci Rep. 2017 Sep 21;7(1):12066. doi: 10.1038/s41598-017-11683-2.

8.

Integrated management of atrial fibrillation including tailoring of anticoagulation in primary care: study design of the ALL-IN cluster randomised trial.

van den Dries CJ, Oudega R, Elvan A, Rutten FH, van de Leur SJCM, Bilo HJG, Hoes AW, Moons KGM, Geersing GJ.

BMJ Open. 2017 Sep 18;7(9):e015510. doi: 10.1136/bmjopen-2016-015510.

9.

Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation-Related Mild Ischemic Stroke: A Randomized Clinical Trial.

Hong KS, Kwon SU, Lee SH, Lee JS, Kim YJ, Song TJ, Kim YD, Park MS, Kim EG, Cha JK, Sung SM, Yoon BW, Bang OY, Seo WK, Hwang YH, Ahn SH, Kang DW, Kang HG, Yu KH; Phase 2 Exploratory Clinical Study to Assess the Effects of Xarelto (Rivaroxaban) Versus Warfarin on Ischemia, Bleeding, and Hospital Stay in Acute Cerebral Infarction Patients With Non-valvular Atrial Fibrillation (Triple AXEL) Study Group.

JAMA Neurol. 2017 Oct 1;74(10):1206-1215. doi: 10.1001/jamaneurol.2017.2161.

PMID:
28892526
10.

Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.

Horinaka S, Sugawara R, Yonezawa Y, Ishimitsu T.

Br J Clin Pharmacol. 2018 Jan;84(1):79-87. doi: 10.1111/bcp.13429. Epub 2017 Oct 18.

11.

Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.

Wang K, Li H, Kwong WJ, Antman EM, Ruff CT, Giugliano RP, Cohen DJ, Magnuson EA; ENGAGE AF‐TIMI 48 Trial Investigators.

J Am Heart Assoc. 2017 Aug 11;6(8). pii: e006703. doi: 10.1161/JAHA.117.006703.

12.

Prognostic factors of clinical endpoints in elderly patients with atrial fibrillation during a 2-year follow-up in China: An observational cohort study.

Wang H, Wang HJ, Chen YD, Tao T, Guo YT, Zhao XN, Liu HB, Wang YT.

Medicine (Baltimore). 2017 Aug;96(33):e7679. doi: 10.1097/MD.0000000000007679.

13.

Analysis of geographical variations in the epidemiology and management of non-valvular atrial fibrillation: results from the RAMSES registry.

Doğan V, Başaran Ö, Biteker M, Özpamuk Karadeniz F, Tekkesin Aİ, Çakıllı Y, Türkkan C, Hamidi M, Demir V, Gürsoy MO, Tek Öztürk M, Aksan G, Seyis S, Ballı M, Alıcı MH, Bozyel S, Kırma C; and Collaborators.

Anatol J Cardiol. 2017 Oct;18(4):273-280. doi: 10.14744/AnatolJCardiol.2017.7709. Epub 2017 Aug 11.

14.

Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.

Limdi NA, Brown TM, Shendre A, Liu N, Hill CE, Beasley TM.

Pharmacogenet Genomics. 2017 Oct;27(10):347-355. doi: 10.1097/FPC.0000000000000298.

PMID:
28806200
15.
16.

Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores.

Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, Valdés M, Vicente V, Lip GYH, Marín F.

J Am Heart Assoc. 2017 Jul 20;6(7). pii: e006490. doi: 10.1161/JAHA.117.006490.

17.
18.

Venous Thromboembolism Prophylaxis on General Internal Medicine Units: Are Patients Well Served by Current Practice?

Mejilla A, Guirguis M, Koshman S, Bungard TJ.

Can J Hosp Pharm. 2017 May-Jun;70(3):200-206. Epub 2017 Jun 30.

19.

Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.

Pisters R, van Vugt SPG, Brouwer MA, Elvan A, Ten Holt WL, Zwart PAG, Kirchhof P, Crijns HJGM, Hemels MEW.

Neth Heart J. 2017 Oct;25(10):551-558. doi: 10.1007/s12471-017-1009-9.

20.

Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.

Leef GC, Hellkamp AS, Patel MR, Becker RC, Berkowitz SD, Breithardt G, Halperin JL, Hankey GJ, Hacke W, Nessel CC, Singer DE, Fox KAA, Mahaffey KW, Piccini JP.

J Am Heart Assoc. 2017 Jun 14;6(6). pii: e004663. doi: 10.1161/JAHA.116.004663.

Supplemental Content

Support Center